|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7200 NOK | -4.00% |
|
-10.00% | -47.83% |
| 06-30 | Exact Therapeutics to Delist from Euronext Growth Oslo in October | MT |
| 06-26 | EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial | RE |
Company Valuation: EXACT Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 884 | 521.9 | 360 | 385 | 237.9 | 87.3 |
| Change | - | -40.97% | -31.02% | 6.95% | -38.21% | -63.3% |
| Enterprise Value (EV) 1 | 724.4 | 419.9 | 292.3 | 339.7 | 139 | 63.39 |
| Change | - | -42.03% | -30.4% | 16.24% | -59.09% | -54.39% |
| P/E | -26.7x | -8.9x | -8.96x | -7.95x | -2.49x | -1x |
| PBR | 5.54x | 4.94x | 5.53x | 8.54x | 2.06x | 2.84x |
| PEG | - | -0.1x | 0.3x | -0.6x | 37,599x | 0.11x |
| Capitalization / Revenue | - | 10,035,840,481x | 791,979,644x | 86,354,110,363x | - | 1,479,718,949x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -21.3x | -7.28x | -7.44x | -7.27x | -2.72x | -0.77x |
| EV / EBIT | -20.9x | -7.1x | -7.17x | -7.02x | -2.63x | -0.75x |
| EV / FCF | -45.7x | -12.1x | -15.1x | -11.6x | -4.42x | -1.14x |
| FCF Yield | -2.19% | -8.25% | -6.62% | -8.64% | -22.6% | -87.8% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.104 | -1.954 | -1.34 | -1.51 | -1.51 | -1.375 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 0.052 | 0.4545 | 0.004458 | - | 0.059 |
| EBITDA 1 | -33.95 | -57.66 | -39.3 | -46.75 | -51.08 | -81.81 |
| EBIT 1 | -34.7 | -59.11 | -40.77 | -48.38 | -52.85 | -84.88 |
| Net income 1 | -33.09 | -58.59 | -40.1 | -48.33 | -52.33 | -86.97 |
| Net Debt 1 | -159.7 | -102 | -67.7 | -45.23 | -98.89 | -23.91 |
| Reference price 2 | 29.5000 | 17.4000 | 12.0000 | 12.0000 | 3.7600 | 1.3800 |
| Nbr of stocks (in thousands) | 29,968 | 29,992 | 29,997 | 32,081 | 63,263 | 63,263 |
| Announcement Date | 5/18/21 | 5/30/22 | 4/21/23 | 4/18/24 | 4/9/25 | 4/9/26 |
1NOK in Million2NOK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.63M | |
| 34.6x | 6.07x | 18.79x | 0.95% | 49.92B | |
| -23.69x | 348.89x | -22.4x | -.--% | 40.23B | |
| 25.19x | 2.79x | 12.06x | -.--% | 34.55B | |
| 44.97x | 4.49x | 28.67x | -.--% | 33.09B | |
| 30.52x | 8.33x | 21.46x | 0.41% | 27.51B | |
| 32.72x | 5.32x | 24.23x | -.--% | 15.92B | |
| 24.09x | 2.05x | 9x | 1.11% | 13.86B | |
| -22.69x | 14.88x | -22.26x | -.--% | 13.52B | |
| Average | 18.21x | 49.10x | 8.69x | 0.31% | 25.4B | |
| Weighted average by Cap. | 19.77x | 66.17x | 9.63x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EXTX Stock
- Valuation EXACT Therapeutics
Select your edition
All financial news and data tailored to specific country editions
